Navigation Links
ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
Date:8/30/2010

and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2010 and 2011, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2011.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.ThermoGenesis Corp.Web site: http://www.thermogenesis.comContact: Investor Relations+1-916-858-5107, orir@thermogenesis.com
'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
2. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
3. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
5. ThermoGenesis Presentation at Rodman & Renshaw Conference
6. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
7. ThermoGenesis Says FDA Concurs with Plan for Previously Announced AXP(TM) Bagset Recall
8. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
9. ThermoGenesis Provides Update on Fiscal 2009 Results
10. ThermoGenesis Announces Expanded Collaboration With Celling Technologies
11. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 Deerfield Management Company, L.P. ... Fund, L.P., which will invest in groundbreaking advancements in ... diseases, cancer, and orphan diseases. The venture capital fund ... therapeutics are developed and improve the way healthcare is ... the largest healthcare-focused venture funds in the sector, will ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
(Date:7/28/2015)... 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has granted to German life sciences entrepreneurs with ... commercialization of biotechnology (collectively, the "Optionee"), an option ... tumor vaccine technology (the "Technology"), including AEZS-120, the ... is ready to enter a Phase 1 clinical ...
(Date:7/28/2015)... 2015  Faced with increasing challenges such as ... than symptomatic, the global healthcare industry today is ... of curing or significantly changing the course of ... towards regenerative medicine as a viable alternative. ... human health with the potential to resolve unmet ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... Vincis inventions, such as this barrel spring, are old enough ... never produced. Over the past decade, the economy has ... assets, such as patents. A patent for a novel medical ... tool to facilitate rational drug design in the pharmaceutical industry ...
... productivity and communications tools now ubiquitous, organizations of ... to promote more effective communication and collaboration among ... role in organizations, the belief that technology by ... and behavior of an organization, particularly a dysfunctional ...
... developer to describe a Web site, youre likely to learn about ... youre likely to learn a lot about pinball. , ,A pinball ... works not the mechanical side of working that involves ASP, ... attracts and retains customers. By thinking of the Internet as a ...
Cached Biology Technology:Patent essentials for business owners: from patent to profit 2Patent essentials for business owners: from patent to profit 3Patent essentials for business owners: from patent to profit 4Patent essentials for business owners: from patent to profit 5Dont rely on information technology to change corporate culture 2Dont rely on information technology to change corporate culture 3My 50 cents: Web sites and pinball machines 2My 50 cents: Web sites and pinball machines 3My 50 cents: Web sites and pinball machines 4
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... used peas to show that one copy of a gene (allele) ... In the progeny, the inherited genes are expressed at the right ... thought that although gene products could be modified during the life ... mutation. Now it appears that one copy of some ...
... ELECTRONIC 222 TO ORDER CLASS II ... ... the leading,provider of outsourced hospital pharmacy I.V. compounded solutions, has,expanded ... ordering of Schedule II,Controlled Substances versus the more time-consuming traditional ...
... May Concern Law Enforcement Departments, TAMPA, Fla., ... STIY), the leader in electro-stun technology, today,announced that ... purchased Taser brand stun products an opportunity to ... devices in exchange,for price concessions., Ron Bellistri, ...
Cached Biology News:Genome communication 2Genome communication 3Genome communication 4PharMEDium Announces National Rollout of Electronic 222 Ordering Initiative 2Stinger Systems To Offer Taser Trade-In Program 2
Recombinant Rat Fas Ligand/TNFSF6...
Blimp-1 (H-150)...
... ATPase α-1, clone C464.6 GenBank ... Purified Na + /K + ATPase ... outer medulla Formulation: 0.1M Tris-glycine, pH 7.4, ... Assurance: routinely evaluated in immunoblot on rat ...
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: